JP2008510453A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510453A5
JP2008510453A5 JP2007516810A JP2007516810A JP2008510453A5 JP 2008510453 A5 JP2008510453 A5 JP 2008510453A5 JP 2007516810 A JP2007516810 A JP 2007516810A JP 2007516810 A JP2007516810 A JP 2007516810A JP 2008510453 A5 JP2008510453 A5 JP 2008510453A5
Authority
JP
Japan
Prior art keywords
peptide
nva
nle
sequence
sekifyv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007516810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510453A (ja
JP5166025B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/021609 external-priority patent/WO2006009920A2/en
Publication of JP2008510453A publication Critical patent/JP2008510453A/ja
Publication of JP2008510453A5 publication Critical patent/JP2008510453A5/ja
Application granted granted Critical
Publication of JP5166025B2 publication Critical patent/JP5166025B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007516810A 2004-06-17 2005-06-17 エピトープアナログ Expired - Fee Related JP5166025B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58100104P 2004-06-17 2004-06-17
US58096204P 2004-06-17 2004-06-17
US60/581,001 2004-06-17
US60/580,962 2004-06-17
PCT/US2005/021609 WO2006009920A2 (en) 2004-06-17 2005-06-17 Epitope analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008155749A Division JP2008283979A (ja) 2004-06-17 2008-06-13 エピトープアナログ

Publications (3)

Publication Number Publication Date
JP2008510453A JP2008510453A (ja) 2008-04-10
JP2008510453A5 true JP2008510453A5 (enExample) 2008-08-07
JP5166025B2 JP5166025B2 (ja) 2013-03-21

Family

ID=35198081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007516810A Expired - Fee Related JP5166025B2 (ja) 2004-06-17 2005-06-17 エピトープアナログ
JP2008155749A Ceased JP2008283979A (ja) 2004-06-17 2008-06-13 エピトープアナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008155749A Ceased JP2008283979A (ja) 2004-06-17 2008-06-13 エピトープアナログ

Country Status (10)

Country Link
US (5) US8202841B2 (enExample)
EP (2) EP1765858B1 (enExample)
JP (2) JP5166025B2 (enExample)
KR (2) KR20070056042A (enExample)
AU (1) AU2005265182B2 (enExample)
CA (1) CA2571168A1 (enExample)
IL (2) IL180101A (enExample)
MX (1) MXPA06014768A (enExample)
SG (1) SG153827A1 (enExample)
WO (1) WO2006009920A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
KR20070056042A (ko) 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP2385059A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
NZ587601A (en) * 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
US7511118B2 (en) * 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
US20070192033A1 (en) * 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
US8396671B2 (en) * 2006-02-16 2013-03-12 Microsoft Corporation Cluster modeling, and learning cluster specific parameters of an adaptive double threading model
US8706421B2 (en) * 2006-02-16 2014-04-22 Microsoft Corporation Shift-invariant predictions
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
WO2008017517A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
US8121797B2 (en) * 2007-01-12 2012-02-21 Microsoft Corporation T-cell epitope prediction
CN101657213B (zh) * 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
EP3533461A3 (en) 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
EP2152890A1 (en) * 2007-05-23 2010-02-17 MannKind Corporation Multicistronic vectors and methods for their design
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
EP2490713A2 (en) 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
CA2781248A1 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
US8933014B2 (en) 2010-03-11 2015-01-13 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
US9345748B2 (en) 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
US10023847B2 (en) 2010-11-25 2018-07-17 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
WO2012076059A1 (en) * 2010-12-09 2012-06-14 Stichting Het Nederlands Kanker Instituut Immune restricted peptides with increased efficacy
WO2012088414A1 (en) 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020051566A1 (en) * 2018-09-07 2020-03-12 Immunotope, Inc. Vaccines with enhanced immune response and methods for their preparation
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
AU2023241306B2 (en) * 2022-10-05 2024-10-03 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6417165B1 (en) * 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
DE4128684A1 (de) * 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
EP1757695A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5747271A (en) 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US6548064B1 (en) 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6025470A (en) * 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
EP1147212B1 (en) * 1999-02-05 2009-08-26 The University Of Melbourne T helper cell epitopes
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
KR20020079731A (ko) * 1999-11-05 2002-10-19 액소닉스, 인코포레이티드. 아밀로이드, 아밀로이드-유사 침착물, 또는 β-쉬이트가풍부한 그의 병리학적 전구체로의 비정상적 단백질 폴딩과관련된 질환의 치료에 있어서 생체내에서 사용하기에적합한 펩티드 동족체 및 유사체
US6605711B1 (en) 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
JP4615805B2 (ja) * 1999-11-15 2011-01-19 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用
EP2177534A3 (en) * 1999-11-18 2010-07-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
EP1118860A1 (en) 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
JP2003524016A (ja) 2000-02-23 2003-08-12 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途
CA2405568A1 (en) * 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2002069907A2 (en) 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
WO2003064457A1 (en) * 2002-01-29 2003-08-07 Antisense Pharma Gmbh A method for inhibiting 'melanoma inhibitory activity' mia
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1482963A4 (en) * 2002-03-08 2010-06-09 Univ Texas CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN
AU2003274463B2 (en) * 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2003261254A1 (en) * 2002-07-31 2004-02-16 Ludwig Institute For Cancer Research Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
WO2004016643A2 (en) 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
CA2499123A1 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
JP5127224B2 (ja) * 2003-06-17 2013-01-23 マンカインド コーポレイション 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
US20050118186A1 (en) 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
KR20070056042A (ko) 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US20060159689A1 (en) 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Similar Documents

Publication Publication Date Title
JP2008543314A5 (enExample)
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
GB2439474A (en) LI-Key/Antigenic epitope hybrid peptide vaccines
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2018509935A5 (enExample)
JP2006187292A5 (enExample)
DE60030450D1 (de) Von MUC-1 abgeleitete Peptide
JP2010536333A5 (enExample)
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
JP2012516140A5 (enExample)
AU2003239659A8 (en) Peptide epitopes common to antigens of the same multigene family
SE9101433D0 (sv) Recombinant dna sequence and its use
JP2021520818A5 (enExample)
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
JP2006514820A5 (enExample)
JP2002517193A5 (enExample)
JP2008521795A5 (enExample)
ATE412745T1 (de) Antiangiogene peptide vom n-terminus von endostatin
WO2003106616A3 (en) $ G (B) MICROGLOBULIN MEMBRANE ANCHORED COVALENTLY LINKED TO PEPTIDE EPITOPES OF CLASS I MHC
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
ATE357526T1 (de) Modifizierte hcv peptid-impfstoffe
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
UA101140C2 (ru) Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины
EP1842911A4 (en) HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS